Prøve GULL - Gratis

Medical devices need separate regulatory framework

Bio Spectrum

|

Decemeber 2019

Medical devices need separate regulatory framework

Medical devices need separate regulatory framework

The vast majority of India’s medical devices of which is nearly 80 per cent import-dependent, are unregulated for quality and safety. While many of these products may have regulatory certifications in other countries, the reality is that a considerable number of them are being exported from countries that do not regulate their exports. The medical devices market in India is over $15 billion (Rs 105,000 crore) and projected to grow to $50 billion by 2025 and is the fourth-largest in Asia.

Thirty years have gone by since the 1st medical device was regulated as a drug in 1989. A comprehensive regulatory framework is nearly in sight with the Draft MEDICAL DEVICES (Safety, Effectiveness & Innovation) Bill from NITI Aayog to be shortly proposed as a Separate Law.

Our policymakers in Health Ministry were surprisingly undecided and seemed to be in no urgency to usher in a ‘Patient Safety Medical Devices Law to protect patients, even after the recent ICIJ implant files or J&J incident, or the most recent ban on Transvaginal Pelvic Mesh by US Food and Drug (FDA). As Ministry of Health & Family Welfare (MoHFW) had been surprisingly very reluctant to draft a separate law preferring to attempt to amend the Drugs Act and Central Drugs Standard Control Organization (CDSCO) has a conflict of interest to empower itself the industry watchers are waiting with anxiety the details of the Draft Medical Devices Bill that NITI Aayog is reportedly working upon in consultation with other stakeholder departments and ministries to address the regulatory vacuum & the national patient safety concerns.

FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum

Bio Spectrum

WHO certifies Suriname malaria-free

Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation

Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.

time to read

1 min

August 2025

Bio Spectrum

Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab

Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.

time to read

1 min

August 2025

Bio Spectrum

Illumina buys SomaLogic for $425 M to accelerate proteomics business

Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26

Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.

time to read

1 min

August 2025

Bio Spectrum

WHO highlights risks associated with use of semaglutide medicines

The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin

Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru

AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Novo Nordisk launches injectable Semaglutide for weight management in India

Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?

India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.

time to read

12 mins

August 2025

Translate

Share

-
+

Change font size